A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma

Starting soon · Phase 1/Phase 2

Conditions studied: Multiple Myeloma

In brief

This is a phase 1/2 multicenter, open-label, first-in-human study of IBI3003. It includes a phase 1 dose escalation and expansion section to identify maximum tolerated dose(MTD)/recommended Phase 2 Dose(RP2D) of IBI3003, plans to enroll 54\~360 subjects, and a phase 2 stage to explore efficacy, safety and tolerability of IBI3003 at RP2D in multiple myeloma

Key facts

Study ID

NCT07336472

Run by

Fortvita Biologics (USA)Inc.

People needed

360

Starts

2026-04-01

Expected to finish

2028-09-30

Last updated by the study team

2026-02-25

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participants in Parts 1 \& 2 must satisfy all of the following criteria to be enrolled in the study:
• Age ≥18 years.
• Documented initial diagnosis of multiple myeloma according to IMWG diagnostic criteria.
• Multiple myeloma is defined as clonal bone marrow plasma cells ≥10% or biopsy-proven bony or extramedullary plasmacytoma, and any one or more of the following myelomadefining events:
• Evidence of end organ damage that can be attributed to the underlying plasma cell proliferative disorder, specifically: Hypercalcemia: serum calcium >0.25 mmol/L (>1 mg/dL) higher than the upper limit of normal or corrected serum calcium >2.75 mmol/L (>11 mg/dL) Renal insufficiency: creatinine clearance <40 mL/min or serum creatinine >177 μmol/L (>2 mg/dL) Anemia: hemoglobin value of >2 g/dL below the lower limit of normal, or a hemoglobin value <10 g/dL Bone lesions: one or more osteolytic lesions on skeletal radiography, CT, or PET-CT
• Any one or more of the following biomarkers of malignancy:
• Clonal bone marrow plasma cell percentage ≥60% Involved: uninvolved serum free light chain ratio ≥100 (involved FLC level must be
• ≥100 mg/L) >1 focal lesions on MRI studies (at least 5 mm in size)
• Relapsed or refractory measurable multiple myeloma (R/R MM) following prior treatment with ≥3 lines of systemic anti-myeloma therapy that include at least a proteasome inhibitor (PI), an immunomodulatory drug (IMiD) agent, and an anti-CD38-based therapy, and with limited or no therapeutic options that are likely to offer a favorable risk/benefit profile; participants must be relapsed or refractory to their last anti-myeloma regimen.
• Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1
• At least one of the following measurable disease indicators:
• Serum M-protein ≥5 g/L (for IgA and IgD subtypes, quantitative immunoglobin measurements could be used as substitutions for M-protein)
• Urine M-protein ≥200 mg/24h
• Serum free light chain (FLC) test: affected FLC level ≥100 mg/L and abnormal serum FLC ratio (<0.26 or >1.65)
• Adequate hematologic, hepatic, renal and cardiac function:
• Blood count: absolute neutrophil count ≥1.0×10\^9/L, hemoglobin ≥70 g/L, and platelet count ≥50×10\^9/L (values must be achieved without growth factors or blood transfusions within 7 days prior to first dose)
• Hepatic function: aspartate aminotransferase (AST) and alanine aminotransferase (ALT) both ≤2.5× upper limit of normal (ULN) and total bilirubin (TBIL) ≤1.5×ULN
• Renal function: calculated creatinine ≥30 mL/min by the Cockcroft-Gault Equation
• Cardiac function: Left ventricular ejection fraction (LVEF) ≥50%
• Life expectancy ≥3 months.
• Women of childbearing potential and fertile men who are sexually active must agree to use a highly effective method of contraception (<1% / year failure rate) during the study and for 90 days after the last dose level of study drug. Contraception must be consistent with local regulations or standards regarding the use of birth control methods by participants participating in clinical trials. Women and men must agree not to donate or bank eggs (ova, oocytes) or sperm, respectively, during the study and for 90 days after the last dose level of study drug.
• Participants with the ability to understand and give written informed consent for participation in this trial, including all evaluations and procedures as specified by this protocol.
• Willing and able to adhere to the complete schedule of assessments and all prohibitions and restrictions specified in this protocol

You may not qualify if…

• Participants who meet any of the following criteria will be disqualified from entering the study:
• Known active central nervous system (CNS) involvement or exhibits clinical signs of meningeal involvement of multiple myeloma.
• Active amyloidosis, plasma cell leukemia, Waldenstrom macroglobulinemia, POEMS syndrome, or solitary plasmacytoma, or smoldering multiple myeloma (MM) as defined by the IMWG criteria.
• Spinal cord compression that results in limited self-care at present or within 6 months prior to informed consent, or that is expected to cause such limitations during Study participation.
• History of primary immunodeficiency.
• Current or previous other malignancy within 3 years of study entry, except cured basal or squamous cell skin cancer, superficial bladder cancer, prostate intraepithelial neoplasm, carcinoma in situ of the cervix, or other noninvasive or indolent malignancy.
• Allogeneic hematopoietic stem cell transplantation within the last 6 months, or autologous stem cell transplantation within the last 3 months prior to the first administration of the study drug.
• History of organ transplantation.
• Active graft-versus-host disease.
• Thromboembolism or cerebrovascular events (e.g., myocardial infarction, unstable angina, transient ischemic attack, cerebrovascular accident, deep vein thrombosis [unless associated with complications of central venous access], or pulmonary embolism) within 6 months prior to the first dose of study drug.
• Pulmonary compromise requiring supplemental oxygen use to maintain adequate oxygenation.
• Known allergies, hypersensitivity, or intolerance to IBI3003 or its excipients (refer to Investigator's Brochure).
• Prior toxicities that have not resolved to ≤Grade 1 prior to study treatment administration except for stable chronic toxicities (≤Grade 2) not expected to resolve (e.g., stable Grade 2 peripheral neurotoxicity)
• Prior antitumor therapy as follows, prior to the first dose of study drug:
• Gene modified adoptive cell therapy (e.g., chimeric antigen receptor modified T cells, natural killer cells) within 8 weeks.
• Targeted therapy, epigenetic therapy, or treatment with an investigational drug or an invasive investigational medical device within 14 days or at least 5 half-lives, whichever is longer.
• Antibody treatment (e.g., monoclonal antibody, bispecific antibody) for multiple myeloma within 21 days.
• Cytotoxic therapy (including antibody-drug conjugates) within 14 days.
• Proteasome inhibitor therapy within 14 days Immunomodulatory agent therapy within 7 days.
• Radiotherapy within 21 days. However, if the radiation field covered ≤5% of the bone marrow reserve, the participant is eligible irrespective of the end date of radiotherapy.
• Cancer vaccine received within 3 months.
• Use of immunosuppressive therapy within 28 days of the start date of study treatment.
• Immunosuppressive therapy includes, but is not limited to, cyclosporine A, tacrolimus, and mycophenolate mofetil, but does not include corticosteroids given as part of an antimyeloma regimen. Participants receiving corticosteroids must be at a dose level ≤10 mg/day of prednisone equivalent for at least 7 days prior to the start of study treatment administration.
• Live or live attenuated vaccine administered within 4 weeks prior to start of study treatment, or anticipated need for live or live attenuated vaccine during the study.
• Uncontrolled diseases, including:

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.